In the U.S., a curative hepatitis C pill course often runs $14,000–$28,000 with discounts; list prices can exceed $60,000 before insurance.
Hepatitis C is curable for most people with short courses of direct-acting antivirals (DAAs). What you pay depends on the drug, the number of weeks, your insurance, and whether you qualify for savings programs. This guide breaks down typical prices, why bills vary, and smart ways to cut the number you see at checkout.
What A Complete Course Usually Costs
Today’s DAA regimens are oral tablets taken for 8 to 12 weeks in most cases. Cash prices and discount-card totals cluster in a band that many pharmacies quote during checkout calls. Brand-name list prices sit much higher, but insurers and savings programs bring the number down for many patients. The table below summarizes realistic ranges per full course in the U.S., based on current manufacturer disclosures, pharmacy discount data, and drug references.
| Regimen (Usual Duration) | Cash/Discount Range* | Brand List Price Signal† |
|---|---|---|
| Glecaprevir/Pibrentasvir (8 weeks) | $14,000–$26,000 per course | ~$13,200 per month WAC (8 weeks ≈ $26,400) |
| Sofosbuvir/Velpatasvir (12 weeks) | $20,000–$30,000 per course | ~$24,920 per month list (12 weeks ≈ $74,760) |
| Ledipasvir/Sofosbuvir (8–12 weeks) | $66,000–$100,000 per course (older brand pricing) | Historic list ~$94,500 for 12 weeks |
*Ranges reflect common U.S. pharmacy discount pricing snapshots and coupon quotes in 2024–2025. †List prices are manufacturer reference figures and rarely match what insured patients pay. Sources: manufacturer price pages and drug references (Mavyret WAC; Epclusa list price; Harvoni course cost; Epclusa discount pricing).
Why Prices Swing So Much
Two people on the same drug can face wildly different totals. Pharmacy contracts change prices. Insurers negotiate rebates. Savings cards carve down cash totals. Medicaid and Medicare rules cap what many patients spend. Even the number of bottles matters: eight weeks costs less than twelve.
Drug Choice And Weeks On Therapy
Many patients without cirrhosis clear the virus in 8 weeks on glecaprevir/pibrentasvir. Others need 12 weeks of sofosbuvir/velpatasvir. Some special situations use 12 weeks of sofosbuvir/velpatasvir/voxilaprevir. Fewer weeks usually means a smaller bill. Your clinician follows the AASLD-IDSA recommendations to match regimen and duration to your profile. You can read the living guidance at the joint HCV site from the liver and infectious-disease societies (HCV Guidance).
Insurance Type
Commercial plans often require prior authorization, then apply copays or coinsurance. Medicare drug coverage changed in 2025: Part D now caps annual out-of-pocket spending on prescriptions at $2,000 across the year, with an option to pay in monthly installments. That cap applies to all covered drugs, including DAAs (CMS Part D $2,000 cap).
Medicaid And Patient Assistance
State Medicaid programs typically cover DAAs and often keep patient copays minimal. Manufacturer assistance can drop costs to very low numbers for eligible patients. For instance, the Epclusa savings site lists common copays near zero for many insured patients and very small totals for Medicaid users (Epclusa savings).
Pharmacy Discount Pricing
Some people pay cash with a coupon. That can bring sofosbuvir/velpatasvir into the mid-to-high four-figure range per month at certain chains, which stacks to the low-to-mid-twenties for a 12-week course (current coupon quotes). Discounts vary by zip code and change often.
“Hep C Treatment Cost” Variations You’ll See (Real Cases)
This section shows realistic bills patients report after approvals and savings are in place. These numbers reflect the most common scenarios seen in clinics and pharmacies across the U.S.
Scenario A: Employer Insurance, Deductible Met
You’re prescribed 8 weeks of glecaprevir/pibrentasvir. The specialty pharmacy confirms prior authorization, and your plan places the drug on a preferred tier. Your copay card from the manufacturer applies. Net out-of-pocket can end up in the double-digits to low triple-digits per fill, adding up to a few hundred dollars across two months.
Scenario B: Medicare Part D (2025 Rules)
With the new $2,000 annual cap, once your combined prescription spending for the year hits the ceiling, you don’t pay more drug cost-sharing. If your DAA fills alone reach that cap, your total for the year stays at $2,000, and you can elect to spread that across the months remaining in the year. Plan premiums and Part B costs are separate from the drug cap (CMS fact sheet).
Scenario C: Medicaid
DAAs are covered in all states, and many programs set copays near zero. Some states remove copays entirely for these drugs. Approval steps vary, but costs at the counter tend to be minimal for eligible enrollees (HCV reimbursement overview).
Scenario D: Cash With A Coupon
No insurance? A coupon price for sofosbuvir/velpatasvir can run in the ballpark of $9,000 per month at some chains, totaling near $27,000 for 12 weeks. Some pharmacies quote lower or higher figures based on their supply contracts (coupon pricing).
What The “Sticker Price” Really Means
Brand list price is a reference used in negotiations. Few people pay it at the counter. Still, it sets the starting point for coinsurance on some plans. Current public figures show Mavyret’s monthly wholesale cost at about $13,200 and Epclusa’s list at about $24,920 per month. Historical pricing placed Harvoni near $94,500 for a 12-week course when it launched, with some current references still citing totals in that zone (Mavyret list price; Epclusa list price; Harvoni cost reference).
What Insurance Actually Pays
Behind the scenes, payers receive confidential rebates that lower their net spending. Medicaid programs receive substantial mandatory rebates by law, then negotiate more on top of that. This is why your personal copay can be modest even when the brand list price looks steep (Medicaid rebate rules).
Other Costs To Plan For
Beyond the tablets, you’ll have a few line items that make treatment safe and smooth. Many people see just a handful of visits and lab draws. Your clinic may bundle some checks; others bill per service. The second table helps you sketch a simple budget.
| Item | Typical Frequency | Cash Range Each |
|---|---|---|
| Initial Viral Load (HCV RNA) | Baseline; repeat at cure check | $80–$200 |
| Comprehensive Metabolic Panel | Baseline; mid-treatment per clinic | $10–$60 |
| Fibrosis Assessment (Non-invasive) | Baseline | $50–$350 |
| Clinic Visit (Telehealth or In-person) | 1–3 visits | $75–$250 |
| SVR12 Lab (Cure Check at 12 Weeks Post-therapy) | Once | $80–$200 |
| HAV/HBV Vaccination (if needed) | Per schedule | $50–$200 |
Ranges reflect typical U.S. cash prices from national labs and clinics offering transparent menus. Insurance often shrinks these amounts. Your clinic can quote exact figures in your network.
Ways To Pay Less Without Delays
Use A Plan’s Preferred Drug
Plans favor certain DAAs. When options are clinically similar for your profile, the preferred pick lowers your coinsurance and speeds approval.
Leverage Savings Cards And Foundations
Commercial insurance users often stack a copay card from the manufacturer with plan coverage. Income-based assistance can help cash-pay patients who meet eligibility rules. Manufacturer portals list current offers and contact lines (Mavyret assistance; Epclusa assistance).
Ask About Authorized Generics
Some brands have authorized generics sold through a sister company at lower list prices. Pharmacies can tell you if those are in stock and billable under your benefits (authorized generic program).
Pick A Single Pharmacy And Stick With It
Switching mid-course can retrigger approvals and delay refills. One specialty pharmacy keeps paperwork tidy and helps your team monitor adherence and side-effect checks.
Use The New Medicare Part D Cap
If you’re on Medicare, the 2025 rule capping drug out-of-pocket costs at $2,000 for the year lets you plan with certainty. Ask your plan to spread payments monthly across the year so a single fill doesn’t strain your budget (Part D details).
What You Get For The Money
Cure rates exceed 95% with current DAA regimens in routine care. Clearing the virus lowers the risk of liver scarring, cancer, and costly complications. Public health agencies call for treatment for nearly everyone with detectable infection because the payoff is large and quick. See CDC’s summary of benefits and the push to treat more people (CDC VitalSigns).
How Clinics Decide The Right Regimen
Teams follow the AASLD-IDSA living guidance. They check your viral load, look for cirrhosis, scan for drug interactions, and confirm other conditions. Most adults without cirrhosis are eligible for simplified treatment paths, which keeps visits and lab work light and costs predictable (HCV Guidance).
Sample Budget Walkthrough
Let’s map a typical 12-week sofosbuvir/velpatasvir course under three common setups. These are ballpark planning numbers; your quotes may differ.
Employer Plan With Copay Card
- Drug: 3 fills at $50–$150 each after copay card → $150–$450 total.
- Visits and labs: $150–$500 combined, depending on network.
- Total: roughly $300–$950.
Medicare Part D In 2025
- Drug: capped at $2,000 annual out-of-pocket across all prescriptions for the year.
- Visits and labs: usually modest copays; many clinics keep these lean.
- Total: plan for up to $2,000 for drugs plus small medical copays.
Cash With Coupon
- Drug: around $20,000–$30,000 for a 12-week course at current coupon quotes.
- Visits and labs: $300–$900 combined in typical cash menus.
- Total: roughly $20,300–$30,900.
Global Note On Affordability
International programs and generic markets show far lower per-course prices in several countries, paired with broad access campaigns. That kind of scale has helped drive down costs outside the U.S. over the past decade (global pricing data; comparative price analyses).
Quick Method Note
This guide pulls current list-price disclosures from manufacturers, widely used drug references, active coupon quotes, and authoritative policy pages. Clinical statements align with the joint AASLD-IDSA guidance, and access notes reflect published CMS rules for 2025. Pricing changes often; your pharmacy and plan can quote exact numbers for your fill date and location.
Bottom Line: Budget, Apply Savings, Start Therapy
If you have coverage, the out-of-pocket number is often far lower than the sticker you see online. Medicare’s 2025 cap helps retirees plan. Medicaid frequently keeps patient costs near zero. Cash-pay patients can still land a workable total using coupon pricing and authorized generics where available. The cure is short, monitoring is light, and the payoff is massive for your long-term liver health. Your care team and pharmacist can pull the exact price ladder for you and get you started.